Background: Although meningiomas are common intracranial tumors, multiple meningiomas (MMs) are rare entities in patients without neurofibromatosis type 2. Previous studies suggest most sporadic MMs are of monoclone in origin. Objective: To elucidate the clonal relationship between two sporadic meningiomas from the same patient by using the next-generation sequencing (NGS) platform. Methods: Two MMs, located frontally and parietally on the right side, were surgically removed from a 52-year-old male. Pathological examinations and whole exome sequencing were performed on tumor samples, followed by Sanger sequencing validation. Results: MMs were diagnosed as secretory and fibrous subtypes, respectively, on histology (WHO grade I) and tumor DNA exhibited distinctive somatic mutation patterns. Specifically, the secretory subtype carried more single nucleotide variant while the fibrous subtype had much higher copy number variation. Besides, the two tumors demonstrated different mutation profiles in predisposing genes and known driver mutations. For example, the secretory subtype had missense mutations in TRAF7 and KLF4, while the fibrous subtype had frameshift deletion of NF2 gene in addition to copy number loss of NF2 and SMARCB1, genetic events that have already been associated with the development of meningiomas. Significantly mutated gene analysis revealed novel mutations of LOC729159 in the secretory subtype and RPGRIP1L and DPP6 in the fibrous subtype. Sanger sequencing validated important point mutations in TRAF7 (c.1678G>A, p.G560S), KLF4 (c.1225A>C, p.K409Q) and CDH11 (c.169T>G, p.W57G). Conclusion: Our data suggest the two meningiomas might develop independently in this patient and molecular subtyping by NGS is a valuable supplement to conventional pathology. Further study is needed to ascertain whether these novel genetic events are tumorigenic or simply passenger mutations, as well as their clinical implications
Introduction
Meningioma is the most common intracranial tumor developed from the arachnoid cells of the meninges. Although meningioma can affect both genders, its incidence is much higher among females than males. The majority of meningiomas are benign, and histologically, they can be classified into various subtypes, such as meningothelial, fibrous, psammomatous, microcystic, and secretory meningiomas. Atypical and malignant meningiomas are rare (~5%) and have a slight male dominance. 1 Various genetic abnormalities have been associated with the development of meningiomas. 2 Historically, loss of chromosome 22 and focal chromosomal deletion in 1p, 6q, 14q, and 18q were first observed. Later, deletion and inactivation of neurofibromin 2 (NF2) gene, a tumor suppressor gene on chromosome 22q12, has been identified as the most common genetic event in patients with both sporadic meningiomas and neurofibromatosis type 2. 3 The advent of the nextgeneration sequencing (NGS) technology further revealed important genetic aberrations in the development of meningiomas not associated with neurofibromatosis type 2 (NF2) abnormality, [4] [5] [6] [7] [8] [9] such as TNF receptor-associated factor 7 (TRAF7), Krupplelike factor 4 (KLF4), v-akt murine thymoma viral oncogene homolog 1 (AKT1), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), smoothened, frizzled family receptor (SMO) and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 (SMARCB1). It is common for patients with NF2 to develop multiple meningiomas (MMs). However, the incidence of sporadic MMs in patients without a history of NF2 is low. 10 It is much less common to find these sporadic
MMs bearing different histological features in the same patient. 11 The etiology of MM is still being debated because of two hypotheses for the development of MMs, ie, monoclonal or independent. 12 The monoclonal hypothesis suggests that MMs originate from a certain neoplastic transformed clone that subsequently spreads along the meninges to form multi-foci. 13, 14 This hypothesis is supported by the observations that most sporadic MMs presented the same histological features. 15 However, it is also possible for MMs that evolve independently and are driven by different key genetic events, such as the cases of MMs showing different histological types or grades. 12 Nevertheless, most of the studies on the etiology of MM were performed based on histological and cytogenetic evidence. To our knowledge, the authors reported here the first comprehensive genomic profiling with whole exome sequencing (WES) on two meningiomas of different histological types in the same patient. Our results revealed distinctive somatic mutation burdens in the two tumors and supported the independent clonal origins hypotheses for the current case.
Methods

Patient recruitment
A 52-year-old male presented with headaches for 2 months was recruited from Second Affiliated Hospital of Wenzhou Medical University. Physical and neurological examinations were performed to confirm whether the patient has pathological signs. Surgery was performed in one stage for resection of both tumors which then were sent for pathological examinations. The patient received detailed information on the study and provided his written informed consent prior to inclusion in the study and has given written informed consent for the publication of information about his case. The present study complied with the Declaration of Helsinki and the experimental protocols and informed consents were approved by the Hospital Institutional Ethics Committee.
DNA extraction and whole-exome sequencing
DNA from the two meningioma tissues and the corresponding patient's peripheral lymphocytes (control) were isolated by standard methods, as described before. 16 The quality of isolated genomic DNA was verified by using 1% agarose gel electrophoresis and Qubit® DNA Assay Kit in Qubit® 2.0 Fluorometer (Life Technologies, CA, USA). For the WES protocol, libraries were prepared for each sample with an Agilent SureSelect Human All Exon kit (Agilent Technologies, Santa Clara, CA, USA) following manufacturer's recommendations and index codes were added to each sample. A total amount of 0.6 μg genomic DNA per sample was used as input material for the DNA sample preparation. Libraries products were purified using AMPure XP system (Beckman Coulter, Beverly, MA, USA) and quantified using the Agilent high sensitivity DNA assay on the Agilent Bioanalyzer 2100 system. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using Hiseq PE Cluster Kit (Illumina) according to the manufacturer's instructions. After cluster generation, the DNA libraries were sequenced on Illumina Hiseq platform and 150 bp pairedend reads were generated.
Variant calling and bioinformatics analysis
FASTQ files of exomes obtained from the three samples (one from peripheral blood and two different tumors from the same patient) were first examined by QC steps to generate high-quality clean data. Valid sequencing data were 
Results
Clinical characteristics of the patient
A 52-year-old male has presented with headaches for 2 months. Physical and neurological examination revealed normal sensation and muscle strength, normal reflexes and negative pathological signs. There was no evidence of neurofibromatosis either. Preoperative magnetic resonance imaging (MRI) scan showed a right frontal tumor with strong homogenous contrast enhancement, marked perifocal edema, and significant midline shift (Figure1A-C). Another well-demarcated and homogenously enhancing tumor was also found at the right parietal convexity, but with minimal perifocal edema (Figure1E-G). Surgery was performed in one stage and both tumors were successfully totally resected and sent for pathological examinations. The postoperative course was uneventful, and his symptoms improved after surgery. He was discharged in one week postoperatively and follow-up MRI scan 8 months later confirmed the complete removal of both tumors ( Figure 1D , H). 
Histopathological examination
Histopathological examination of right frontal meningioma revealed the tumor cells were in a form of syncytium-like appearance, with unclear boundaries between the cells. The nucleus was oval with fine chromatin and some of the nucleus was transparent in the middle. Cells were arranged in large lobulated structures or formed a small swirling structure. Some tumor cells were partially epithelialdifferentiated and the intraepithelial microgland contained eosinophilic substances (Figure 2A ). Immunohistochemistry (IHC) showed CK (+), Vimentin (+++), EMA (sporadic +), CEA (+), S-100 (−), Ki-67 (~1%), CD34 (−), ER (−) and PR (+). Histopathological examination of the right parietal meningioma showed spindle-shaped tumor cells, parallel or bundled in a cross-shaped arrangement. There was formation of swirling structure in focal areas, with calcification scattered in a small amount of mature adipose tissues. The shapes of nucleus were long spindle, fatty spindle, or oval, with fine chromatin and some nucleus were transparent ( Figure 2B ). IHC showed Vimentin (+++), Ki-67 (~1%), CK (−), and EMA (+). The right frontal meningioma was pathologically diagnosed as secretory meningioma (WHO grade I) whereas the right parietal one was fibrous meningioma (WHO grade I).
Genetic analysis of the two meningiomas
Given the different subtypes in both meningiomas, we tried to examine the genetic differences and the clonal relationship between two sporadic meningiomas. We applied WES on the two meningiomas to investigate all variants annotated with in-house pipeline. Somatic mutation analysis revealed, in the secretory subtype, there was a total of 1,343 SNVs (59 in the CoDing Sequence (CDS)) and 57 InDels (3 in the CDS) in a total of 1,085 genes ( Figure 3A) . Whereas 1034 SNVs (28 in the CDS) and 32 InDels (3 in the CDS) in a total of 798 genes were identified in the fibrous subtype (see Tables S1 and S2 ). In addition, we found that there were 128 common genes with somatic mutations between two subtypes, whereas there were only 37 common somatic mutations (SNVs and InDels) in these common genes ( Figure 3A) . Focusing on the exons, there were no common genes with somatic mutations in exons of the whole genome between two subtypes ( Figure 3B ). Furthermore, we also performed CNV analysis that revealed only 13 gain counts in the secretory subtype, while there were 109 gain counts and 10 loss counts, including copy number loss of NF2 and SMARCB1, in the fibrous subtype (see Table S3 ).
The two tumors also demonstrated different mutation profiles in terms of predisposing gene mutation and known driver gene mutation. For predisposing gene mutation analysis, the secretory subtype had the highest mutation burden. Besides, as compared with the control, it contained missense mutations in TRAF7, KLF4, and CDH11, in-frame deletion in ELN, a nonsense mutation in PDE4DIP, as well as mutations in the splice sites of NUP214, KDM6A, and ZMYM2. In contrast, the fibrous subtype had a missense mutation in PDE4DIP, in-frame deletion in ZRSR2, frameshift deletion in NF2, and splice site mutation of ZMYM2 ( Figure 4A ). Known driver gene mutation analysis indicated the missense mutations of ABCB1, AHNAK, CDH11, TRAF7 and H3F3A, and frame-shift deletion of KMT2D in the secretory subtype. Whereas the fibrous subtype had missense mutations of GMPS and frame-shift deletion of A B NF2 ( Figure 4B ). Significantly mutated genes analysis showed missense mutations of LOC729159 in the secretory subtype and RPGRIP1L and DPP6 in the fibrous subtype ( Figure 4C) . A whole-genome view of the two samples confirmed a higher number of SNV and InDel events in secretory subtype while a more prominent CNV abnormality in the fibrous subtype ( Figure 5 ). Subsequent validation by Sanger sequencing confirmed nonsynonymous mutations in KLF4 (c.1225A>C, p.K409Q), CDH11 (c.169T>G, p.W57G) and TRAF7 (c.1678G>A, p.G560S) in secretory subtype ( Figure 6 ).
Discussion
The definition of MM is generally accepted as two or more than two spatially separated meningiomas that have developed from at least two distinct brain regions. Although MMs can occur in patients with predisposing conditions such as NF2, hereditary SWI/SNF complex deficiency syndromes, 22 Cowden syndrome, 23 Turner syndrome 24 and Rubinstein-Taybi syndrome, 25 Despite the lack of knowledge on the incidence of meningiomas of different histological subtypes in the same patient, there is a keen interest in revealing the etiology of MMs. Since the majority of surgically removed MMs showed the same histopathological features, it is likely they might derive from one single clone that disseminates through the subarachnoid space during the long history of this benign condition. Another hypothesis, which is supported by the observations of MMs presenting different pathological features, is that tumors can develop independently at multiple foci through different neoplastic transition mechanisms. Previous investigations have mainly focused on the molecular mechanisms underpinning samples from a patient with sporadic MM. They identified three common mutational events (NF2, FAM109B, and TPRXL) for all tumors as well as unique mutations for each individual tumor. Therefore, they proposed a monoclonal origin for their particular case. That patient underwent multiple surgeries for progressive tumor growth, including a dorsal meningioma (1975), an olfactory sulcus meningioma (1987) and multiple neoplastic nodules from the frontoparietal convexity and falx (1990), over a period of 15 years. Although all tumors were diagnosed histologically as transitional meningioma, the authors did not specify which four tumor tissues, among the multiple samples they had collected, had been sequenced.
To the best of our knowledge, our current study is the first to adopt WES on the genetic profiling of two histologically different primary sporadic MMs in the same patient. Our results showed distinctive genetic features underlying them and thus we support an independent clonal origin in the current case. For example, secretory subtype featured with a higher frequency of SNV and InDel events while the fibrous subtype had a more prominent CNV abnormality. Our results also identified some key mutations that have been associated with the development of meningiomas. PCM1  MSH2  RANBP17  CDK12  KMT2D  EML4  MN1  RANBP2  KMT2A  ARID2  CDC42EP1  ITK  MLLT4  CANT1  PDE4DIP  ZMYM2  CDH11  ZRSR2  ZNF384  MAML2  KLF4  KDM6A  NF2 Specifically, mutations in TRAF7, KLF4, and CDH11 for the secretory subtype and deletion of NF2, copy number loss of NF2 and SMARCB1 for the fibrous subtype. There are several comprehensive review articles on the germline and somatic mutations underlying the pathogenesis meningiomas 1, 34, 35 and a detailed analysis of those known gene mutations and their complex pathway interactions are beyond the scope of the current paper. However, we would discuss here briefly on important mutant genes that have been confirmed by Sanger sequencing. For example, we identified a c.1225A>C (p.K409Q) in KLF4, which is consistent with previous reports. [36] [37] [38] KLF4 belongs to a family of DNA-binding transcriptional regulators and were suggested to be involved in some cancers as potential tumor suppressor, despite the fact that KLF4 K409Q mutation being specific for meningioma. 39, 40 In contrast, the TRAF7 c.1678G>A (p.G560S) mutation in our secretory subtype is relatively novel compared with previous reports (N520S, G536S, K615E, R641C and R641H). 30 TRAF7 depletion by RNA interference has been shown to result in resistance to TNFα cytotoxicity and TRAF7 downregulation was observed in breast cancer expression and was proposed to contribute to p53 accumulation. 41, 42 Nevertheless, similar to KLF4, TRAF7 mutation is highly specific for meningioma. This concomitant TRAF7/KLF4 mutation pattern was seen in about 8% of meningiomas and provided both diagnostic (secretory subtype) and prognostic value (better prognosis compared with NF2 type). 30 Besides, there might be potential benefits by targeting either KLF4, TRAF7 or both, though further research is needed. Moreover, these authors suggest the establishment of a classification system on meningiomas by combing clinical feature, histology, and genetic mutation to better refine personalized treatments. Yuzawa et al 30 classified meningiomas into seven genotypes: NF2, TRAF7/KLF4, TRAF7/ AKT1, SMO, "Others," "Complex," and "None". They also found these genotypes were related to clinical features such as tumor location, and histological types and grades. Interestingly, both the fibrous subtype and the secretory subtype in our case matched the proposed NF2 genotype and TRAF7/KLF4 genotype. Another recent study further proposed a classification and grading system for meningioma based on DNA methylation pattern. 43 They have shown the six methylation classes are better at predicting recurrence and prognosis than the WHO classification system. Specifically, the methylation class (MC) ben-1 is featured by NF2 mutation, 22q deletion with predominant histology of fibroblastic, transitional and atypical. While the MC ben-2 is featured by TRAF7, KLF4, SMO, and AKT mutations, balanced chromosome and secretory, transitional and meningothelial histology. Accordingly, the two meningiomas of our current case matched the MC ben-1 and MC ben-2 subclass. Therefore, our sequencing results support these molecular classification systems. In 2016 WHO classification of the tumors of the central nervous system, 44 molecular classification has already been applied in the diagnosis of gliomas, as their genetic makeup can significantly influence patients' prognosis and choice of treatments. Therefore, it is also promising to incorporate molecular classification of meningiomas into existent WHO histological classification system.
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Conclusion
Genetic profiling with NGS is a valuable supplement to conventional pathological diagnosis in answering the questions regarding the clonal origin of MMs. Further study is needed to ascertain whether these genetic abnormalities are tumorigenic or simply passenger mutations, as well as their clinical implications. Current efforts on genetic profiling of meningiomas, together with further investigation on the associations between genetic abnormalities, histology, and patients' prognosis, will help to establish a more integrate diagnosis on meningiomas including MMs.
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